Immunicum's uplisting to Nasdaq Stockholm postponed
March 24 2017 - 11:35AM
GOTHENBURG, Sweden, March 24,
2017 - Immunicum AB (publ; First North Premier: IMMU.ST) a
biopharmaceutical company advancing a novel immuno-oncology
treatment against a range of solid tumors, announced today that
Nasdaq Stockholm's listing committee has postponed the decision on
Immunicum's application for admission to trading. The committee
noted that Immunicum has formalized and conformed its corporate
governance and communication procedures to the additional
requirements imposed on companies listed on Nasdaq Stockholm
and that the company needs to demonstrate that it will
continue to apply them for a longer period before the committee can
make a final decision on the company's application.
The company will announce the final decision from
the listing committee following the communication of the decision,
which is not expected before the third quarter of 2017.
About Immunicum AB
(publ)
Immunicum AB (First North Premier: IMMU.ST) is a clinical stage
company developing novel immuno-oncology therapies against a range
of solid tumors. The Company's lead compound, INTUVAX® is currently
being evaluated in clinical trials for the treatment of kidney
cancer, liver cancer and gastrointestinal stromal tumors. INTUVAX®
was designed to combine the best of two worlds: a cost-effective
cell-based (allogeneic) and off-the-shelf therapy that is capable
of triggering a highly personalized and potentially long-lasting
immune response against tumor cells throughout the body.
www.immunicum.com
For more information, please
contact:
Carlos de Sousa, CEO, Immunicum
Ph: +46 (0) 31 41 50 52
E-mail: info@immunicum.com
Media Contact
MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
Ph: +49 89 2424 3494 or + 49 175 571 1562
E-mail: gschweitzer@macbiocom.com
The Company's Certified Adviser is Redeye
AB
Ph: + 46 8 545 013 31
www.redeye.se
The information in this press
release is disclosed pursuant to the EU Market Abuse Regulation.
The information was released for public disclosure through the
agency of the contact person set out above on March 24, 2017 at
4.35 pm CET
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Immunicum AB via Globenewswire
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Apr 2023 to Apr 2024